1 / 65

THE AMERICAN GERIATRICS SOCIETY Geriatrics Health Professionals.

POLYPHARMACY Wendolyn Gozansky , MD, MPH Associate Professor Division of Geriatric Medicine University of Colorado Denver. AGS. THE AMERICAN GERIATRICS SOCIETY Geriatrics Health Professionals. Leading change. Improving care for older adults. CONTENTS. Drugs and the elderly

summer
Download Presentation

THE AMERICAN GERIATRICS SOCIETY Geriatrics Health Professionals.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. POLYPHARMACYWendolynGozansky, MD, MPHAssociate ProfessorDivision of Geriatric MedicineUniversity of Colorado Denver AGS THE AMERICAN GERIATRICS SOCIETY Geriatrics Health Professionals. Leading change. Improving care for older adults.

  2. CONTENTS • Drugs and the elderly • Pharmacodynamic and pharmacokinetic changes with aging • Drug knowledge and compliance • Prudent prescribing

  3. 12% of the population is aged 65+ Drug Use in the Elderly

  4. 12% of the population is aged 65+ 30% of all prescription drug use is among those aged 65+ Drug Use in the Elderly

  5. 12% of the population is age 65+ 30% of all prescription drug use is among those aged 65+ 50% of all OTC drug use is among those aged 65+ Drug Use in the Elderly

  6. ADVERSE DRUG REACTIONS (ADRs) • 106,000 deaths in 1994

  7. ADVERSE DRUG REACTIONS (ADRs) • 106,000 deaths in 1994 • $177 billion in 2000

  8. ADVERSE DRUG REACTIONS (ADRs) • 106,000 deaths in 1994 • $177 billion in 2000 • For every $1 spent on drugs, $1 spent on ADRs

  9. ADVERSE DRUG REACTIONS (ADRs) • 106,000 deaths in 1994 • $177 billion in 2000 • For every $1 spent on drugs, $1 spent on ADRs • 95% of ADRs considered to be predictable

  10. ADVERSE DRUG REACTIONS (ADRs) • 106,000 deaths in 1994 • $177 billion in 2000 • For every $1 spent on drugs, $1 spent on ADRs • 95% of ADRs considered to be predictable • 7-fold increased risk in the elderly • Related to polypharmacy • Changes in pharmacodynamics/pharmacokinetics • Drug-disease interactions

  11. Exponential Relation Between Polypharmacy and ADRs Nolan L. JAGS. 1988;36(2):142-149.

  12. CONTENTS • Drugs and the elderly • Pharmacodynamic and pharmacokinetic changes with aging • Drug knowledge and compliance • Prudent prescribing

  13. Pharmacodynamics Response that occurs when a drug interacts at its receptor

  14. Pharmacodynamic Changeswith Aging Increased response (eg, opiates)

  15. Pharmacodynamic Changeswith Aging Increased response (eg, opiates) Decreased response (eg, beta-agonists)

  16. Pharmacokinetics Drug concentration at the site of action

  17. Pharmacokinetics • Drug concentration at the site of action • 4 determinants: • Absorption • Distribution • Metabolism • Elimination

  18. PK Changes with Aging: ABSORPTION  gastric pH  gastric emptying  splanchnic blood flow  intestinal motility Minimal clinical importance

  19. PK Changes with Aging: DISTRIBUTION  fat mass  muscle mass  total body water  albumin (binds acidic drugs)  alpha-1 glycoprotein (binds basic drugs) Clinically important

  20. 20-year-old woman Rosenberg, I. J Nutr. 1997. 127(5):990-991S. Published with permission.

  21. 64-year-old woman 20-year-old woman Rosenberg, I. J Nutr. 1997. 127(5):990-991S. Published with permission.

  22. 64-year-old woman 20-year-old woman Rosenberg, I. J Nutr. 1997. 127(5):990-991S. Published with permission.

  23. 64-year-old woman 20-year-old woman Rosenberg, I. J Nutr. 1997. 127(5):990-991S. Published with permission.

  24. PK Changes with Aging:METABOLISM  hepatic mass  hepatic blood flow  first-pass metabolism Clinically important: Longer half-life of drugs undergoing phase I metabolism (eg, diazepam vs lorazepam)

  25. PK Changes with Aging:ELIMINATION  renal mass  renal blood flow  glomerular filtration rate Most clinically important •  concentration of drugs dependent on renal clearance • Serum creatinine alone does not provide adequate information to guide dosing

  26. Pharmacokinetic Changeswith Aging What is the best formula for estimating GFR in older adults? • Cockcroft-Gault (CG) • Modification of Diet in Renal Disease (MDRD)

  27. CG vERSUS MDRD

  28. CG VERSUS MDRD

  29. Biology of the Patient • Limited functional reserve

  30. Biology of the Patient Disease Compensatory severitymechanisms Symptomatic Asymptomatic Resnick N.M, Marcantonio E.R. The Lancet. 1992;350(9085):1157-1158. Published with permission.

  31. Biology of the Patient • Limited functional reserve • Drug-disease interactions

  32. CONTENTS • Drugs and the elderly • Pharmacodynamic & pharmacokinetic changes with aging • Drug knowledge and compliance • Prudent prescribing

  33. Do you know what’s in your patient’s medicine cabinet? ~20% of drugs found on home inventory were not revealed by physician interview Most frequently unreported class of drugs?

  34. Do you know what’s in your patient’s medicine cabinet? ~20% of drugs found on home inventory were not revealed by physician interview Most frequently unreported class of drugs? BENZODIAZEPINES!!!

  35. Altered Compliance • Under-utilization • Over-utilization • Enforced compliance

  36. Relation Between Polypharmacyand Number of Prescribers

  37. Relation Between Polypharmacyand Compliance

  38. Methods to Improve Compliance •  # of drugs, prescribers, and pharmacies • Once-daily or twice-daily dosing • Pill boxes • Medication reminder charts •  frequency of clinic visits

  39. CONTENTS • Drugs and the elderly • Pharmacodynamic & pharmacokinetic changes with aging • Drug knowledge and compliance • Prudent prescribing

  40. Avoid the Prescribing Cascade Drug 1 BMJ. 1997;315:1096-1099.

  41. Avoid the Prescribing Cascade Drug 1 Adverse effect misinterpreted as new medical condition Rochon, P. BMJ. 1997;315:1096-1099. Published with permission.

  42. Avoid the Prescribing Cascade Drug 1 Adverse effect misinterpreted as new medical condition Drug 2 Rochon, P. BMJ. 1997;315:1096-1099. Published with permission.

  43. Avoid the Prescribing Cascade • HCTZ – Allopurinol • NSAIDs – Antihypertensives • Metoclopramide – Carbidopa/levodopa • Cholinesterase inhibitors – Tolterodine

  44. Beware of Drug-Drug Interactions (DDIs) • 100% chance of DDIs with 8 drugs

  45. Beware of Drug-Drug Interactions (DDIs) • 100% chance of DDIs with 8 drugs • Nearly 50% of community-dwelling geriatric patients had at least one DDI

  46. Beware of Drug-Drug Interactions (DDIs) • 100% chance of DDIs with 8 drugs • Nearly 50% of community-dwelling geriatric patients had at least one DDI • DDIs can result in ADRs or suboptimal dosing

  47. Prudent Prescribing Principles • Know your patients and their drug cabinets

  48. Prudent Prescribing Principles • Know your patients and their drug cabinets • Educate yourself and your patients

  49. Prudent Prescribing Principles • Know your patients and their drug cabinets • Educate yourself and your patients • Understand biases in clinical trials

More Related